Skip to main content
SpringerLink
Log in

Cytokines and Cytokine Gene Transfer in Cancer Treatment

  • Chapter
Strategies for Immunointerventions in Dermatology

  • 83 Accesses

Abstract

It is generally accepted that the spontanous generation of cancer cells is a common event and that the immune system ensures strict surveillance with the detection and elimination of these cells. In order to fight cancer, the idea of using the destructive power of immunologic reactions is easily visualized in autoimmune diseases and by the rejection of allografts in transplantation medicine. A number of clinical observations in human malignant melanoma suggest that a particularly vigorous immune response occurs [18,28,29,31]. It is believed that the immune attack against melanoma cells may be responsible for the occurrence of spontanous melanoma regressions and for the concomittant destruction of melanocytes in benign lesions, leading to clinical phenomena such as halo nevi, uveitis, and vitiligo in melanoma patients. In addition, tumor dormancy with a prolonged interval between the occurrence of the primary tumor and melanoma metastases has been interpreted as indicating the existence of specific, immunologic antitumor effector mechanisms. These observations, together with anecdotal and clinical reports of tumor regressions following bacterial infections or more specific immune interventions, suggest that melanoma is a good model with which to evaluate the various strategies of immune therapy [28,29,31].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224–227.

    Article  PubMed  CAS  Google Scholar 

  2. Allione A, Consalvo M, Nanni P, Lollini P L, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL) 2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, GM-CSF, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022–6026.

    PubMed  CAS  Google Scholar 

  3. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstem RD (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154:1280–1288.

    PubMed  CAS  Google Scholar 

  4. Blankenstein T (1994) Increasing tumour immunogenicity by genetic modification. Eur J Cancer 30A:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  5. Boon T, Gajewski TF, Coulie PG (1995) From defined human tumor antigens to effective immunization. Immunol Today 16:334–336.

    Article  PubMed  CAS  Google Scholar 

  6. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T (1995) Tumor cells cotransfected with interleukin-7 and B71 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25:2325–2331.

    Article  PubMed  CAS  Google Scholar 

  7. Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48–51.

    Article  PubMed  CAS  Google Scholar 

  8. Columbo MP, Maccalli C, Mattei S, Melani C, Radrizzam M, Parmiani G (1992) Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 2:181–189.

    Article  Google Scholar 

  9. Culver KW (1996) Measuring success in clinical gene therapy research. Mol Med Today 6:234–236.

    Article  Google Scholar 

  10. Dalgleish A (1996) The case for therapeutic vaccines. Melanoma Res 6:5–10.

    Article  PubMed  CAS  Google Scholar 

  11. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Livitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403.

    Article  PubMed  CAS  Google Scholar 

  12. Friedmann T (1996) Human gene therapy - an immature genie, but certainly out of the bottle. Nature Med 2:144–147.

    Article  PubMed  CAS  Google Scholar 

  13. Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3:291–299.

    PubMed  CAS  Google Scholar 

  14. Gilboa E, Lyerly HK (1994) Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biol Ther Cancer Updates 4 (6): 1–16.

    Google Scholar 

  15. Hersey P (1994) Melanoma vaccines - current status and future prospects. Drugs 47:373–382.

    Article  PubMed  CAS  Google Scholar 

  16. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effecti- vity not superior to a classical adjuvant. Cancer Res 53:714–716.

    PubMed  CAS  Google Scholar 

  17. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458–6462.

    Article  PubMed  CAS  Google Scholar 

  18. Mackensen A, Carcelain G, Viel S, Raynal M-C, Michalaki H, Triebel F, Bosq J, Hercend T (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93:1391–1402.

    Article  Google Scholar 

  19. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11–24.

    Article  PubMed  CAS  Google Scholar 

  20. Marshall E (1995) Gene therapy’s growing pain. Science 269:1050–1055.

    Article  PubMed  CAS  Google Scholar 

  21. Mertelsmann R, Lindemann A, Boehm T, Brennscheidt U, Franke B, Kulmburg P, Lahn M, Mackensen A, Rosenthal FM, Veelken H (1995) Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors. I Mol Med 73:205–206.

    CAS  Google Scholar 

  22. Mitchell MS (1996) Immunotherapy of melanoma. J Invest Dermatol Symp Proc 1:215–218.

    CAS  Google Scholar 

  23. Moller P, Schadendorf D (1997) Somatic gene therapy and its implication for the treatment of malignant melanoma. Arch Dermatol R

    Google Scholar 

  24. Moller P, Sun YS, Dorbic T, Moller H, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D Vaccination with IL-7-gene modified autologous tumor cells enhances tumor- specific T cell precursor frequency and modulates cytokine secretion in patients with advanced malignant melanoma - a clinical phase I study (submitted)

    Google Scholar 

  25. Mosman TR, Sad S (1996) The expanding universe of T-cell subsets: TH1, TH2 and more. Immunol Today 17:138–146.

    Article  Google Scholar 

  26. Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant Bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 93:934–939.

    Article  PubMed  CAS  Google Scholar 

  27. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang I, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307–11311.

    Article  PubMed  CAS  Google Scholar 

  28. Oettgen HF , Old LJ (1991) The history of cancer immunotherapy. In: deVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, principles and practice. Lippincott, Philadelphia, pp 87–96

    Google Scholar 

  29. Old LJ (1981) Cancer immunology: the search for specificity - GHA Clowes Memorial Lecture. Cancer Res 41:365.

    Google Scholar 

  30. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399–415.

    Article  PubMed  CAS  Google Scholar 

  31. Parkinson DR, Houghton AN, Hersey P, Borden Hi i 1992) Biologic therapy tor melanoma. In: Balch CM, Houghton AN, Milton GW, Sober A), Soong S] (eds) Cutaneous melanoma. Lippin- cott, Philadelphia, p 522.

    Google Scholar 

  32. Parmiani G, Colombo MP (1995) Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res 5:295–301.

    Article  PubMed  CAS  Google Scholar 

  33. Rammensee HG, Falk K, Rötzschke 0 (1993) Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1 1:213–244.

    Article  Google Scholar 

  34. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA (1994) Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy Cancer Res 54:3124–3126.

    CAS  Google Scholar 

  35. Ruiter DJ, Mattijssen V, Bröcker K-B, Per rone S (1991) MHC antigens m human melanomas. Semin Cancer Biol 2:35–45.

    PubMed  CAS  Google Scholar 

  36. Schadendorf D, Czarnetzki BM, Wittig B (1995) Clinical protocol - interleukin-7-, interleu- kin-12-, and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 73: 473–477.

    Article  PubMed  CAS  Google Scholar 

  37. Schadendorf D, Henz BM, Wittig B ! 1996) Interleukin 7 trials for melanoma treatment. Mol Med Today 2:143–144.

    Article  Google Scholar 

  38. Schmidt W, Schweighofer T, Herbst E, Maas G, Berger M, Schilcher F, Schaffner G, Birnstiel ML (1995) Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sei USA 92:4711–4715.

    Article  CAS  Google Scholar 

  39. Schmidt-Wolf GD, Schmitt-Wolf IGH (1995) Cytokines and clinical gene therapy. Eur J Immunol 25:1137–1140.

    Article  PubMed  CAS  Google Scholar 

  40. Schmidt-Wolf IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn L) (1994) 1 nterleukin-7 gene transfer in patients with metastatic colon carcinoma, renal carcinoma, melanoma or with lymphoma. Hum Gene Ther 5:1161–1168.

    Article  PubMed  CAS  Google Scholar 

  41. Sherman LA, Chattopadhyay S (1993) The molecular basis of allorecognition. Annu Rev Immunol 11:385–402.

    Article  PubMed  CAS  Google Scholar 

  42. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR Jr, Bloom BR (1991) New use of BCG for recombinant vaccines. Nature 351:456–460.

    Article  PubMed  CAS  Google Scholar 

  43. Tahara H, Lotze M, Robbins PD, Storkus WJ, Zitvogel L (1995) IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 6:1607–1624.

    Article  PubMed  CAS  Google Scholar 

  44. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 57:503–512.

    Article  PubMed  CAS  Google Scholar 

  45. Touchette N (1996) Gene therapy: not ready for prime time. Nat Med 2:7–8.

    Article  CAS  Google Scholar 

  46. Vieweg J, Gilboa E (1995) Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 13:193–201.

    Article  PubMed  CAS  Google Scholar 

  47. Whittington R, Faulds D (1993) Interleukin-2 a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446–514.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH-8091, Zurich, Switzerland

    Günter Burg M.D. (Chairman) (Chairman)

  2. Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH-8091, Zurich, Switzerland

    Reinhard G. Dummer M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schadendorf, D. (1997). Cytokines and Cytokine Gene Transfer in Cancer Treatment. In: Burg, G., Dummer, R.G. (eds) Strategies for Immunointerventions in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60752-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60752-3_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64539-6

  • Online ISBN: 978-3-642-60752-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation